s6y

10-K Annual Report for period ending Dec 31, 2025

Filed
Period
Accession number
0001213900-26-037667

Documents

  1. Annual Report 10-K

Exhibits

  1. 3.4 Certificate of Designation of Series E Convertible Preferred Stock of 20/20 Biolabs, Inc EX-3.4
  2. 4.1 Description of Securities of 20/20 Biolabs, Inc EX-4.1
  3. 4.2 Warrant to Purchase Shares of Common Stock Issued by 20/20 Biolabs, Inc. to Streeterville Capital, LLC on February 19, 2026 EX-4.2
  4. 4.3 Warrant to Purchase Shares of Common Stock Issued by 20/20 Biolabs, Inc. to Maxim Partners LLC on February 19, 2026 EX-4.3
  5. 4.4 Warrant to Purchase Shares of Common Stock Issued by 20/20 Biolabs, Inc. to Streeterville Capital, LLC on February 9, 2026 EX-4.4
  6. 4.5 Warrant to Purchase Shares of Common Stock Issued by 20/20 Biolabs, Inc. to Maxim Partners LLC on February 9, 2026 EX-4.5
  7. 4.7 Warrant to Purchase Shares of Common Stock Issued by 20/20 Biolabs, Inc. to Maxim Partners LLC on November 17, 2025 EX-4.7
  8. 10.2 Secured Convertible Promissory Note Issued by 20/20 Biolabs, Inc. to Streeterville Capital, LLC on February 9, 2026 EX-10.2
  9. 14.1 Code of Business Conduct and Ethics EX-14.1
  10. 19.1 Insider Trading Policy EX-19.1
  11. 97.1 Clawback Policy EX-97.1
Certifications, consents and other formalities 4 Certification
  1. 31.1 Certification EX-31.1
  2. 31.2 Certification EX-31.2
  3. 32.1 Certification EX-32.1
  4. 32.2 Certification EX-32.2
Data files 5 Financial data and other files for software
  1. 101.SCH XBRL Schema File EX-101.SCH
  2. 101.CAL XBRL Calculation File EX-101.CAL
  3. 101.DEF XBRL Definition File EX-101.DEF
  4. 101.LAB XBRL Label File EX-101.LAB
  5. 101.PRE XBRL Presentation File EX-101.PRE

On sec.gov